Managing Partner at Next Frontier Advisors
Mr. Ted Schenkelberg (MBA/MPH), for over 20 years, has worked at the intersection of advanced biotech, global health and business, building organizations seeking to make an impact on human health. He has extensive international experience working across the US, EU, UK, Africa and India.
Currently, Ted is a Managing Partner at Next Frontier Advisors (NFA), a strategic consulting firm advising foundations, companies, universities and philanthropies in the biomedical and global health fields. At NFA, Ted has led international efforts to catalyze work in the Alzheimer’s vaccine space.
Previously, Ted served as Co-Founder, Chief Operating Officer and Chief Strategy Officer at the Human Immunome Project (formerly the Human Vaccines Project), a global NGO working to catalyze AI-based models of the immune system with collaborations including Moderna, GSK, Pfizer, Harvard, Vanderbilt, Lawrence Livermore and others. Prior, Ted led business planning at the International AIDS Vaccine Initiative (IAVI), an NGO operating in 21 countries which has raised over $1 billion for vaccine R&D. He also served as an Equity Analyst and member of the Investment Committee at Carnegie Capital, an asset management firm which oversaw $1 billion in management and administration.
Ted currently serves as a board member at Doctors of the World USA (humanitarian aid) and MesaNova Bio (commercial biotech) and previously served as a board member at the African Services Committee, and the Human Immunome Project European Foundation. Ted was trained at the University of Chicago (MBA), Johns Hopkins (MPH), and Grinnell College (BA). He has also held a post as a Visiting Scientist at the Harvard Chan School.